Skip to main content
Erschienen in: Investigational New Drugs 4/2012

01.08.2012 | SHORT REPORT

Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells

verfasst von: Erika Rimondi, Maria Grazia di Iasio, Arianna Gonelli, Claudio Celeghini, Paola Secchiero, Giorgio Zauli

Erschienen in: Investigational New Drugs | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Excerpt

Osteoprotegerin (OPG) is a soluble member of the tumor necrosis factor (TNF) receptor family, initially characterized for its ability to inhibit the receptor activator of NF-kB ligand (RANKL)-stimulated formation of osteoclasts [1]. OPG also interacts with TNF-related apoptosis inducing ligand (TRAIL) [2], a different member of the TNF super-family whose extracellular domain shares a 35% homology with RANKL [3]. Several studies have demonstrated that OPG is elevated in the serum/plasma of patients affected by different types of cancer (reviewed in [4]), but the potential role of OPG with respect to cancer development/progression is unknown. Among different potential cellular sources of circulating OPG, endothelial cells represent a major source of OPG under basal conditions as well as in response to inflammatory stimuli [5]. Hydrogen sulfide (H2S)—known for decades as a toxic gas—is endogenously generated from cysteine, in reactions catalyzed by cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE) [68]. Mounting data on endogenously generated H2S have now included this gas in the family of gasotransmitters, together with nitric oxide (NO) and carbon monoxide (CO), and its effects are intensively investigated both at the cellular and molecular level [7]. On these bases, the aim of the present study was to investigate in vitro the effect of H2S on the expression and release of OPG by human vascular endothelial cells in the absence or presence of the pro-inflammatory cytokine TNF-α. …
Literatur
1.
Zurück zum Zitat Simonet WS, Lacey DL, Dunstan C et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed Simonet WS, Lacey DL, Dunstan C et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed
2.
Zurück zum Zitat Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in sk-n-mc neuronal cells. J Neurochem 86:126–135CrossRefPubMed Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in sk-n-mc neuronal cells. J Neurochem 86:126–135CrossRefPubMed
3.
Zurück zum Zitat DI Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331–340CrossRefPubMed DI Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331–340CrossRefPubMed
4.
Zurück zum Zitat Zauli G, Melloni E, Capitani S, Secchiero P (2009) Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 66:841–851CrossRefPubMed Zauli G, Melloni E, Capitani S, Secchiero P (2009) Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 66:841–851CrossRefPubMed
5.
Zurück zum Zitat Secchiero P, Corallini F, Pandolfi A et al (2006) An increased osteoprotegerin (OPG) serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169:2236–2244CrossRefPubMed Secchiero P, Corallini F, Pandolfi A et al (2006) An increased osteoprotegerin (OPG) serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169:2236–2244CrossRefPubMed
6.
Zurück zum Zitat Navarra P, Dello Russo C, Mancuso C, Preziosi P, Grossman A (2000) Gaseous neuromodulators in the control of neuroendocrine stress axis. Ann NY Acad Sci 917:638–646CrossRefPubMed Navarra P, Dello Russo C, Mancuso C, Preziosi P, Grossman A (2000) Gaseous neuromodulators in the control of neuroendocrine stress axis. Ann NY Acad Sci 917:638–646CrossRefPubMed
7.
Zurück zum Zitat Wang R (2002) Two’s company, three’s a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J 16:1792–1798CrossRefPubMed Wang R (2002) Two’s company, three’s a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J 16:1792–1798CrossRefPubMed
8.
Zurück zum Zitat Moore PK, Bhatia M, Moochhala S (2003) Hydrogen sulfide: from the smell of the past to the gas of the future? Trends Pharmacol Sci 24:609–611CrossRefPubMed Moore PK, Bhatia M, Moochhala S (2003) Hydrogen sulfide: from the smell of the past to the gas of the future? Trends Pharmacol Sci 24:609–611CrossRefPubMed
9.
Zurück zum Zitat Secchiero P, Candido R, Corallini F et al (2006) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114:1522–1530CrossRefPubMed Secchiero P, Candido R, Corallini F et al (2006) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114:1522–1530CrossRefPubMed
10.
Zurück zum Zitat Secchiero P, Corallini F, Gonelli A et al (2007) Anti-angiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 100:61–69CrossRefPubMed Secchiero P, Corallini F, Gonelli A et al (2007) Anti-angiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 100:61–69CrossRefPubMed
11.
Zurück zum Zitat Re MC, Zauli G, Gibellini D et al (1993) Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of aids patients are committed to apoptotic cell death in culture. AIDS 7:1049–1055CrossRefPubMed Re MC, Zauli G, Gibellini D et al (1993) Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of aids patients are committed to apoptotic cell death in culture. AIDS 7:1049–1055CrossRefPubMed
12.
Zurück zum Zitat Zauli G, Re MC, Furlini G, Giovannini M, LA Placa M (1992) Human immunodeficiency virus type 1 envelope glycoprotein GP120-mediated killing of human haematopoietic progenitors (CD34+ cells). J Gen Virol 73:417–421CrossRefPubMed Zauli G, Re MC, Furlini G, Giovannini M, LA Placa M (1992) Human immunodeficiency virus type 1 envelope glycoprotein GP120-mediated killing of human haematopoietic progenitors (CD34+ cells). J Gen Virol 73:417–421CrossRefPubMed
13.
Zurück zum Zitat Zauli G, Rimondi E, Stea S et al (2008) Trail inhibits osteoclastic differentiation by counteracting rankl-dependent P27KIP1 accumulation in pre-osteoclast precursors. J Cell Physiol 214:117–125CrossRefPubMed Zauli G, Rimondi E, Stea S et al (2008) Trail inhibits osteoclastic differentiation by counteracting rankl-dependent P27KIP1 accumulation in pre-osteoclast precursors. J Cell Physiol 214:117–125CrossRefPubMed
14.
Zurück zum Zitat Mangan SH, Campenhout AV, Rush C, Golledge J (2007) Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res 76:494–505CrossRefPubMed Mangan SH, Campenhout AV, Rush C, Golledge J (2007) Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res 76:494–505CrossRefPubMed
15.
Zurück zum Zitat Zauli G, Corallini F, Bossi F et al (2007) Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 110:536–543CrossRefPubMed Zauli G, Corallini F, Bossi F et al (2007) Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 110:536–543CrossRefPubMed
16.
Zurück zum Zitat Cross SS, Yang Z, Brown NJ et al (2006) Osteoprotegerin (OPG)–a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 118:1901–1908CrossRefPubMed Cross SS, Yang Z, Brown NJ et al (2006) Osteoprotegerin (OPG)–a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 118:1901–1908CrossRefPubMed
17.
Zurück zum Zitat Li L, Moore P (2008) Putative biological roles of hydrogen sulfide in health and disease: a breath of not so fresh air? Trends Pharmacol Sci 29:84–90CrossRefPubMed Li L, Moore P (2008) Putative biological roles of hydrogen sulfide in health and disease: a breath of not so fresh air? Trends Pharmacol Sci 29:84–90CrossRefPubMed
18.
Zurück zum Zitat Szabó C (2007) Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6:917–993CrossRefPubMed Szabó C (2007) Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6:917–993CrossRefPubMed
19.
Zurück zum Zitat Secchiero P, Corallini F, DI Iasio MG, Gonelli A, Barbarotto E, Zauli G (2005) Trail counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105:3413–3419CrossRefPubMed Secchiero P, Corallini F, DI Iasio MG, Gonelli A, Barbarotto E, Zauli G (2005) Trail counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105:3413–3419CrossRefPubMed
Metadaten
Titel
Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells
verfasst von
Erika Rimondi
Maria Grazia di Iasio
Arianna Gonelli
Claudio Celeghini
Paola Secchiero
Giorgio Zauli
Publikationsdatum
01.08.2012
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 4/2012
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-011-9675-8

Weitere Artikel der Ausgabe 4/2012

Investigational New Drugs 4/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.